Crossmark

Pregnant women’s experiences and perceptions of participating in the EVERREST prospective study; a qualitative study

Published Online: 2019-04-30

Published Print: 2019-12

Authors

Harvey, Merryl E.

David, Anna L.

Dyer, Jade

Spencer, Rebecca http://orcid.org/0000-0002-3019-0322
Funding

Funding for this research was provided by:

European Union Seventh Framework Programme (305823)

National Institute for Health Research University College London Hospitals Biomedical Research Centre (BRC326/III/RS/101350)
License Information

Text and Data Mining valid from 2019-04-30

Version of Record valid from 2019-04-30
More Information

Article History

Received: 15 July 2018

Accepted: 1 April 2019

First Online: 30 April 2019

Ethics approval and consent to participate

: Approval for the study was obtained from London Stanmore Research Ethics Committee (13/LD/1254). All participants gave written informed consent which was reaffirmed immediately prior to the interview.

: All participant quotes are anonymised using a number allocated soley for the purposes of this study. Participants were informed about the inclusion of anonymised quotes in publications as part of the consent process.

: ALD is a shareholder in Magnus Growth, a company that is aiming to take to market a new treatment for placental insufficiency. The remaining authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current